Trial Profile
A Phase 4, Open-Label Study of the Pharmacokinetics and Safety of XARTEMIS XR (7.5 Oxycodone Hydrochloride/325 mg Acetaminophen) in Postsurgical Adolescent Subjects (Ages 12 to 17) With Moderate to Severe Acute Pain
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 24 Jan 2020
Price :
$35
*
At a glance
- Drugs Oxycodone/paracetamol (Primary)
- Indications Acute pain
- Focus Pharmacokinetics
- Sponsors Mallinckrodt Inc.
- 24 May 2018 Status changed from recruiting to discontinued due to business decision
- 27 Apr 2016 Planned End Date changed from 1 Apr 2016 to 1 Mar 2017.
- 27 Apr 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Mar 2017.